摘要
近年来,我国生物医药产业的飞速发展以及出入境特殊物品的增加,在给人民健康带来益处的同时,对我国的生物安全监管体系带来一定挑战。本文主要介绍了美国疾病控制与预防中心(CDC)对入境传染性物质的监管制度,主要包括联邦选择药剂程序和进口许可证程序。本研究对中美入境传染性物质的监管制度进行了比较研究,并探讨了美国入境传染性物质的监管制度对我国的启示。
With the development of Chinese biomedical industry and the increase of special items for entry and exit,it has brought challenges to Chinese bio-safety regulatory system in recent years.It introduces CDC's regulatory system for entry infectious substances in the United States,including Federal Select Agent Program and Import Permit Program.It conducted a comparative study on the regulatory systems of entry infectious substances in China and the United States,and explored the implications for China about the regulatory system.
作者
符丽媛
王沛
孙涛
翁贇琦
吴海磊
Fu Liyuan;Wang Pei;Sun Tao;Weng Yunqi;Wu Hailei(Suzhou Industrial Park Customs,Suzhou Jiangsu 215021,China;Suzhou Customs,Suzhou Jiangsu 215000,China;Nanjing Customs,Nanjin Jiangsu 210001,China;Animal,Plant and Food Inspection Center of Nanjing Customs,Nanjing Jiangsu 211106,China)
出处
《口岸卫生控制》
2023年第3期6-10,共5页
Port Health Control
基金
南京海关科研项目(2023KJ16)。
关键词
美国
传染性物质
监管
United States
Infectious substances
Supervise